Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.72 USD | -8.70% | -9.06% | -9.92% |
03-22 | Lyra Therapeutics Files $300 Million Mixed Shelf Offering | MT |
03-21 | Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 1.38M 110M | Sales 2025 * | 782K 62.56M | Capitalization | 282M 22.57B |
---|---|---|---|---|---|
Net income 2024 * | -68M -5.44B | Net income 2025 * | -82M -6.56B | EV / Sales 2024 * | 204 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 361 x |
P/E ratio 2024 * |
-4.67
x | P/E ratio 2025 * |
-4.24
x | Employees | 88 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.47% |
Latest transcript on Lyra Therapeutics, Inc.
1 day | -8.70% | ||
1 week | -9.06% | ||
Current month | -24.12% | ||
1 month | -27.72% | ||
3 months | -2.28% | ||
6 months | +60.00% | ||
Current year | -9.92% |
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 31/12/14 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 12/09/21 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 10/07/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 15/02/22 |
W. Smith
BRD | Director/Board Member | 68 | 18/11/19 |
James Tobin
BRD | Director/Board Member | 79 | 06/03/22 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 4.72 | -8.70% | 157,240 |
25/04/24 | 5.17 | -1.15% | 105,303 |
24/04/24 | 5.23 | +0.38% | 120,741 |
23/04/24 | 5.21 | 0.00% | 228,918 |
22/04/24 | 5.21 | +0.39% | 240,842 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.92% | 282M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- LYRA Stock